PD-1 and PDL-1 Inhibitors Market 2021 Estimated to Reach a Valuation of USD 74.34 Billion by 2027, at a CAGR of 17.45 % Over the Forecast Period of 2027, Covering COVID-19 impact Analysis
Coherent Market Insights released a new market study on 2021-2027 PD-1 and PDL-1 Inhibitors Market with 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed analysis. At present, the market is developing its presence. The Research report presents a complete assessment of the Market and contains a future trend, current growth factors, attentive opinions, facts, and industry validated market data. Report offering you more creative solutions that combine our deep geographic experience, intimate sector knowledge and clear insights into how to create value in your business. The research study provides estimates for 2021-2027 PD-1 and PDL-1 Inhibitors Market Forecast till 2027*.
Request Here For Market Latest Insights: https://www.coherentmarketinsights.com/insight/request-pdf/173
PD-1 and PDL-1 inhibitors are a group of checkpoint inhibitors that are being developed for the treatment of cancer. Targeted cancer therapy is the primary objective of extensive research related to cancer drugs. Immune cells in humans are programmed to attack the foreign cell on activation. PD-1 and PDL-1 are among those activation points present on the immune cells. Sometimes cancer cells also use this PD-1 and PDL-1 trigger points to avoid being attacked by the immune cells. Therefore, cancer drugs targeting these cells hold tremendous potential in the cancer treatment market. Approved PD-1 and PDL-1 inhibitor drugs have become blockbuster products. The global PD-1 and PDL-1 inhibitors market is segmented based on the drug type and application as follows:
- Drug Type
- PD-1 inhibitors
- Pembrolizumab (Keytruda)
- Nivolumab (Opdivo)
- PDL-1 inhibitors
- Atezolizumab (Tecentriq)
- Avelumab (Bavencio)
- PD-1 inhibitors
- Non-small cell lung cancer
- Kidney cancer
- Melanoma of the skin
- Bladder cancer
- Merkel cell skin cancer
PD-1 inhibitors are effective in treating different types of chronic disease such as non-small-cell lung carcinoma (NSCLC), kidney cancer, melanoma of the skin, head and neck cancers, bladder cancer, and Hodgkin lymphoma. Opdivo is leading the race with US$ 3.8 Bn in sales in 2016, compared to US$ 1.4 Bn of Keytruda in 2016. Both these drugs have witnessed significant development in past two years with respect to extended therapeutic application and approvals in European countries and Japan.
PDL-1 inhibitors are proven to be effective in NSCLC, bladder cancer, and Merkel cell skin cancer. In March 2017, Avelumab received the U.S. Food and Drug Administration (FDA) approval for metastatic Merkel cell carcinoma (MCC), a rare skin cancer with no approved therapies. The drug therefore, received approval under the accelerated approval process, requiring the developers, Pfizer, Inc. and Merck KGaA to conduct larger clinical trials to establish complete safety and efficacy of the drug. The drug is also being tested for bladder cancer, NSCLC, gastric cancer, ovarian cancer, and renal cancer, under the JAVELIN clinical trial program. Extended therapeutic applications widens the potential opportunity for the drugs in the global PD-1 inhibitors and PDL-1 inhibitors market.
Active research activities to spur the global PD-1 and PDL-1 inhibitors market growth
Increasing research and development activities in cancer treatment is expected to drive growth of the global PD-1 and PDL-1 inhibitors market during the forecast period. PD-1 and PDL-1 biomarkers are also called immune checkpoints. Trails from Merck & Co. and Bristol-Myers Squibb have shown PD-1 and PDL-1 inhibitors to be efficient in patients expressing higher level of PD-1 and PDL-1 biomarkers, restricting the potential market to only these patients. Therefore, all of the big pharma companies in the global market of PD-1 and PDL-1 inhibitors are combining the PD-1 and PDL-1 inhibitors with other targeted cancer drugs to cater to a larger set of population. The global PD-1 and PDL-1 inhibitors market is poised to grow significantly with more product developments in the segment. There are 65 clinical studies in phase 2 and phase 3 phase globally. Commercialization of a novel drug in this segment would be a great booster for the growth for the global PD-1 and PDL-1 inhibitors market.
A major share of the revenue of the global PD-1 and PDL-1 inhibitors market is currently concentrated in North America, Europe, and Japan as these are the three major revenue generating nations with high insurance coverage, high healthcare investment, and are highly developed pharmaceutical markets. The market players would be eyeing other regions for tapping the cancer treatment market opportunities in those regions. Uncertain regulations challenging the sales of patented pharmaceutical products has been a major deterring factor for global pharmaceutical companies to enter into emerging economies. However, novel rugs for cancer type with no treatment available currently would find positive outlook in these regions, though the high pricing would inhibit their sales in emerging economies.
Key players operating in the global PD-1 and PDL-1 inhibitors market include Pfizer, Inc., Bristol-Myers Squibb, Merck KGaA, AstraZeneca plc, F. Hoffmann-La Roche AG, Merck & Co. Inc., Regeneron Pharmaceuticals, Inc., Novartis AG, and Ono Pharmaceutical Co., Ltd.
Research and development activities related to PD-1 and PDL-1 inhibitors is expected to boost the market growth. For instance, in March 2018, researchers from University Hospital Carl Gustav Carus, Germany, observed that the expression of the inhibitory immune checkpoints PD-L1 and VISTA may explain the poor responsiveness of prostate cancer patients to cytotoxic T lymphocyte antigen-4 blockade and supports the design of a combination therapy targeting both molecules.
In May 3, 2019, researchers from Shin-Kong Wu Ho-Su Memorial Hospital reported that PD-1 inhibitors show anti-tumor effects on advanced malignancies, including metastatic melanoma, advanced cutaneous squamous cell carcinoma, urothelial tumors, and duodenal adenocarcinoma in renal transplant patients.
In August 2019, researchers from Jagiellonian University, Poland, used well-known in vitro methods and revealed that there is no direct binding between CA-170 – the only small-molecule modulator in clinical trials targeting PD-L1 and VISTA proteins and PD-L1.
Purchase this Report at Discount Of US $2000 Flat OFF – https://www.coherentmarketinsights.com/promo/buynow/173
Reasons to Purchase this Report
• Current and future of global PD-1 and PDL-1 Inhibitors Market outlook in the developed and emerging markets • The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period. • Regions/countries that are expected to witness the fastest growth rates during the forecast period • The latest developments, market shares, and strategies that are employed by the major market players
Major Point Answered in PD-1 and PDL-1 Inhibitors Market Research Study are:
- What will be the progress rate of the PD-1 and PDL-1 Inhibitors Market for the conjecture period, 2021-2027?
- What are the prominent factors driving the PD-1 and PDL-1 Inhibitors Market across different regions?
- Who are the major vendors dominating the PD-1 and PDL-1 Inhibitors industry and what are their winning strategies?
- What will be the market scope for the estimated period?
- What are the major trends shaping the expansion of the industry in the coming years?
- What are the challenges faced by the PD-1 and PDL-1 Inhibitors Market?
Request Here Sample Report @ https://www.coherentmarketinsights.com/insight/request-sample/173
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
- CDN Newswire